Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA3: Osimertinib vs Chemotherapy in T790M+ NSCLC
NCT02151981Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02151981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151981.